Skip to content
Journal article

Therapies for dactylitis in psoriatic arthritis. A systematic review

Helliwell P...(+1 more)

Journal of Rheumatology, vol. 33, issue 7 (2006) pp. 1439-1441

  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.
  • N/A


    ScienceDirect users who have downloaded this article.
Sign in to save reference


Dactylitis is a hallmark clinical feature of psoriatic arthritis (PsA). Acute dactylitis appears to be a severity marker for PsA and psoriasis. Traditionally, clinicians have used nonsteroidal antiinflammatory rheumatic drugs and local corticosteroid injections to treat dactylitis, although conventional disease modifying antirheumatic drugs also are recommended. In this systematic review, the limited data on treatments for dactylitis in PsA highlight the need for a valid, reliable, and responsive clinical outcome measure. Infliximab is the only drug to demonstrate significant improvement of dactylitis during a clinical study.

Author-supplied keywords

  • Medline
  • adalimumab
  • biologic factors and agents acting on the immune s
  • clinical feature
  • clinical trial
  • cyclosporin A
  • dactylitis
  • disease marker
  • disease modifying antirheumatic drug
  • drug efficacy
  • etanercept
  • evidence based medicine
  • human
  • infliximab
  • leflunomide
  • meta analysis
  • outcome assessment
  • palliative therapy
  • placebo
  • priority journal
  • psoriatic arthritis
  • review
  • salazosulfapyridine
  • spondyloarthropathy
  • systematic review

Find this document

Cite this document

Choose a citation style from the tabs below